The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAptitude Regulatory News (APTD)

Share Price Information for Aptitude (APTD)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 300.00
Bid: 297.00
Ask: 304.00
Change: 2.00 (0.67%)
Spread: 7.00 (2.357%)
Open: 305.00
High: 309.00
Low: 296.00
Prev. Close: 298.00
APTD Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Update and Notice of Results

18 Jan 2018 07:00

RNS Number : 1872C
Microgen PLC
18 January 2018
 

 

microgen

www.microgen.com

  18 January 2018

 

MICROGEN plc ('Microgen' or 'the Group')

 

TRADING UPDATE & NOTICE OF RESULTS

 

Microgen plc has made excellent progress in 2017. The Group's two businesses continue to execute successfully their declared strategies with Aptitude Software delivering strong organic growth and Microgen Financial Systems continuing its transition towards a business focussed on the Trust & Fund Administration ('T&FA') market. The Aptitude Software business complemented its organic growth strategy with the August 2017 acquisition of California-based RevStream, whilst Microgen Financial Systems acquired Toronto-based T&FA specialist Primacy in February 2017. Both acquisitions continue to perform in line with expectations.

 

Microgen Financial Systems has maintained its focus on the Trust & Fund Administration ('T&FA') market within the wealth management sector benefitting from both organic growth and the contribution from Primacy. The combination of organic growth and focused acquisitions has led to revenues from T&FA representing over 60% of Microgen Financial Systems' revenue in 2017 (2016: 54%), with the T&FA on-going recurring revenue now standing at £8.8 million (2016: £6.9 million), an increase of 28%. The increase in the T&FA on-going recurring revenue base in 2017 was 16%, excluding the acquisition of Primacy. (The on-going recurring revenue base includes recurring revenues contracted but yet to commence and excludes recurring revenues which are currently being received but are known to be terminating in the future).

 

Aptitude Software has continued to make excellent new business progress in the second half of 2017 highlighted by the first RevStream sales under Aptitude Software's ownership and concluding with a strategically important contract with one of the world's largest technology businesses for the recently launched Aptitude Lease Accounting Engine ('ALAE'). New business effort in 2018 will be focussed on further sales of the successful Aptitude Revenue Recognition Engine, ALAE, RevStream and early sales of the new Aptitude Insurance Calculation Engine which addresses the requirements of IFRS 17, a new accounting standard focussed on insurance contracts. Aptitude Software's on-going recurring revenue base now stands at £19.3 million (2016: £12.6 million), an increase of 53%. The increase in the on-going recurring revenue base in 2017 was 30%, excluding the acquisition of RevStream.

 

Microgen anticipates issuing its preliminary results for the year ended 31 December 2017 on 7 March 2018.

 

Contacts

Ivan Martin, Chairman 020-7496-8100

Philip Wood, Chief Financial Officer

 

Darius Alexander, FTI Consulting 020-3727-1063

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCGGUAAGUPRGQM
Date   Source Headline
3rd May 20247:00 amRNSTransaction in Own Shares
1st May 20244:10 pmRNSTotal Voting Rights
30th Apr 20244:46 pmRNSGrant of awards under 2020 Deferred Bonus Plan
29th Apr 20247:00 amRNSTransaction in Own Shares
24th Apr 20247:00 amRNSTransaction in Own Shares
19th Apr 20247:00 amRNSTransaction in Own Shares
17th Apr 20247:00 amRNSTransaction in Own Shares
12th Apr 20247:00 amRNSTransaction in Own Shares
11th Apr 20247:00 amRNSTransaction in Own Shares
10th Apr 20247:00 amRNSTransaction in Own Shares
9th Apr 20247:00 amRNSNotice of 2024 Annual General Meeting
8th Apr 20247:00 amRNSTransaction in Own Shares
4th Apr 20247:00 amRNSTransaction in Own Shares
3rd Apr 20247:00 amRNSTransaction in Own Shares
2nd Apr 20241:46 pmRNSTotal Voting Rights
2nd Apr 20247:00 amRNSTransaction in Own Shares
28th Mar 20247:00 amRNSBLOCK LISTING SIX MONTHLY RETURN
28th Mar 20247:00 amRNSTransaction in Own Shares
27th Mar 20247:00 amRNSTransaction in Own Shares
26th Mar 20247:00 amRNSTransaction in Own Shares
25th Mar 20247:00 amRNSTransaction in Own Shares
22nd Mar 20247:00 amRNSTransaction in Own Shares
21st Mar 20247:01 amRNSAptitude to Accelerate Autonomous Finance
21st Mar 20247:01 amRNSShare buyback programme
21st Mar 20247:00 amRNSAudited Results for Year Ended 31 December 2023
21st Feb 20247:00 amRNSChange of Broker Arrangements
9th Feb 20247:00 amRNSHolding(s) in Company
31st Jan 20247:00 amRNSHolding(s) in Company
22nd Jan 20247:00 amRNSFull Year Trading Update and Notice of Results
4th Jan 20247:00 amRNSFynapse Win
30th Nov 20237:00 amRNSAppointment of Chief Executive Officer
12th Oct 20237:00 amRNSHolding(s) in Company
2nd Oct 20232:17 pmRNSGrant of awards
29th Sep 20237:00 amRNSBLOCK LISTING SIX MONTHLY RETURN
21st Sep 20232:28 pmRNSHolding(s) in Company
20th Sep 20239:32 amRNSHolding(s) in Company
7th Sep 202310:15 amRNSGrant of Awards under Performance Share Plan
23rd Aug 20231:21 pmRNSHolding(s) in Company
23rd Aug 20231:15 pmRNSHolding(s) in Company
28th Jul 202312:18 pmRNSHolding(s) in Company
28th Jul 20237:00 amRNSHolding(s) in Company
27th Jul 20231:52 pmRNSHolding(s) in Company
26th Jul 20237:00 amRNSInterim Results
24th Jul 20235:22 pmRNSHolding(s) in Company
20th Jul 20237:00 amRNSHolding(s) in Company
19th Jul 20237:00 amRNSDirector Retirement
13th Jul 20237:00 amRNSTrading Update and Directorate Changes
23rd Jun 20234:43 pmRNSHolding(s) in Company
16th Jun 20234:22 pmRNSHolding(s) in Company
25th May 20235:22 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.